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The local treatment of DCIS should be different  
than that of early-stage invasive cancer 
Janusz Piekarski
Surgical methods currently applied in the local treatment of pre-invasive ductal carcinoma are largely the same as 
those used in early-stage invasive breast cancer. Both conditions are treated either with tumor excision (combined 
with radiation therapy) or with mastectomy. Comparable proportions of DCIS and early-stage breast cancer patients 
receive the most aggressive form of treatment. Nearly 30% of the former undergo mastectomy. A question thus 
presents itself: is this the way it should be?
The purpose of DCIS treatment is to prevent its progression to invasive disease or detect a hidden invasive compo-
nent. However, in and of itself, DCIS is not a terminal condition and does not directly put life at risk. Indeed, it may be 
a precursor of invasive cancer, but progression is known to occur in as few as 20–30% of untreated patients. At the 
same time, it is a quite heterogeneous diagnostic category. Some ductal carcinomas in situ with the lowest degree 
of malignancy behave more like atypias and show a similar risk of progression, only slightly higher than that for an 
average 65-year-old woman in the general population. It has even been argued that these DCIS cases are not properly 
carcinomas at all; labeling them as “cancer” provokes disproportionate fear in patients and compels physicians to take 
unnecessary and excessive treatment measures. In order to change that, it is first crucial to modify the terminology 
we use: changes with a very low risk of progression toward invasive carcinoma should be labeled as indolent lesions 
of epithelial origin (IDLE). To conclude, the local treatment of pre-invasive carcinoma in most cases should differ from 
that of early-stage invasive cancer. Aggressive methods should be avoided unless specifically required.
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When we ask ourselves whether the local treatment of 
pre-invasive ductal carcinoma should be the same as that 
of early-stage invasive cancer, the answer that immediately 
comes to mind is a resounding “no”. Why? It is enough to 
take a look at available diagnostic and treatment guide-
lines, which all discuss principles applicable to DCIS and 
invasive cancer under separate sections. Examples there 
are aplenty, including the guidelines issued by the Polish 
Oncology Union [1] and the National Consultant for Cancer 
Surgery, American recommendations from the National 
Comprehensive Cancer Network [2] and the MD Anderson 
Cancer Center [3], as well as German guidelines from the 
Arbeitsgemeinschaft Gynäkologische Onkologie [4]. The 
Polish Oncology Union recommends that the choice of 
treatment should rely on the Van Nuys prognostic indica-
tor (VNPI), which takes into account tumor size, the width 
of clear surgical margins, nuclear grade classification, and 
patient age [1]. American and German guidelines do not use 
the VNPI, but also suggest that physicians should base their 
treatment decisions on tumor size and surgical margins.
However, a quick look at the surgical methods currently 
employed in DCIS treatment reveals that they are largely the 
same as those used in patients with early-stage invasive can-
cer. These include mastectomy or tumor excision with (or, in 
exceptional cases, without) accompanying radiation therapy. 
Interestingly, aggressive treatments are used with similar fre-
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quency in patients with DCIS and early-stage invasive cancer. 
A thought-provoking study on the subject was published 
in the Journal of the National Cancer Institute in September 
2015 [5], where Worni et al. tallied up SEER database records 
on DCIS treatment for the period between 1991–2010. The 
study identified a total of 121,080 patients; 23.8% underwent 
unilateral mastectomy, 4.5% had bilateral mastectomy, 43% 
were treated with tumor excision and radiation therapy, and 
excision alone was performed in 26.5%. 2.3% were not oper-
ated on at all. These averaged data, however, fail to reflect 
the changes in treatment methods that occurred over the 
analyzed period. Closer inspection reveals that the proportion 
of patients treated with tumor excision and radiation therapy 
doubled, rising from 24.2% to 46.8% over the time span in 
question. The number of amputations, on the other hand, 
halved, dropping from 44.9% to a mere 19.3%. Interestingly, 
however, the percentage of bilateral mastectomies due to 
non-invasive ductal carcinoma grew from 0% to 8.5%. These 
figures can be summed up very briefly. DCIS patients are be-
ing treated with very aggressive methods; nearly 30% have 
(unilateral or bilateral) mastectomies and 50% undergo tumor 
excision followed by radiation therapy [5]. We might thus 
conclude that, in actual fact, the topical treatment of DCIS 
today is exactly the same as that of early-stage invasive cancer. 
Is this the way it should be? In order to find an answer, we 
should first consider the goal of treatment in both conditions.
The purpose of therapy in invasive breast cancer is clear. 
We are dealing with a potentially fatal disease that, in 2012 
alone, caused as many as 915 thousand deaths throughout 
the European Union [6]. Treatment is geared toward pre-
venting death and prolonging life expectancy; aggressive 
measures are thus fully justified. This is why the comparison 
of methods used in the treatment of early-stage cancer in 13 
European Breast Unit centers does not come as a surprise. 
More than 25% of patients are reported to undergo mastec-
tomy [7]. The figure is well warranted; what might raise a few 
eyebrows, however, is the fact that it is lower than the per-
centage of mastectomies among DCIS patients in the US [5].
What is the objective of treatment in DCIS? The goal is to 
prevent progression to invasive disease or detect a hidden 
invasive component [2]. In and of itself, DCIS is not a fatal 
condition and does not pose a risk to patients’ lives. Diagnosis 
and prevention are important objectives, of course, but do 
they really warrant a 30% amputation rate, including bilateral 
mastectomy in as many as 10% of patients [5, 8]? Mortality 
among women treated for DCIS reaches 3.3% after 20 years 
[9]. Importantly, treatment methods do not seem to have 
a statistically significant impact on treatment results. The 
latter are normally very good. But why shouldn’t they, con-
sidering that the disease is not life-threatening to begin 
with? What does pose a threat to patients’ lives are possible 
diagnostic errors (a failure to detect invasion and take ap-
propriate action) and relapse in the form of invasive disease. 
Indeed, DCIS is recognized as a precursor of cancer, but 
progression only occurs in as few as 20–30% of untreated 
patients [5]. What are the actual figures? As reported by Worni 
et al. [5], approximately 50–60 thousand new DCIS cases are 
diagnosed in the US every year. In the absence of treatment, 
progression may thus be expected to occur in about 15 thou-
sand. This means that as many as 45 thousand patients every 
year are subjected to aggressive and often mutilating treat-
ments for a disease that does not even threaten their lives. 
Of course, a small risk of progression does exist and one 
may well argue that all measures should be taken to make 
sure it does not materialize. It is worth asking, however, 
whether we treat every high-risk patient in the same way. Do 
we always resort to equally aggressive treatment methods? 
Women with BRCA1 and BRCA2 gene mutations are particu-
larly likely to develop breast cancer; more than 80% are at risk 
of the disease. It turns out, however, that only 20% undergo 
prophylactic bilateral mastectomy [10]. How does this com-
pare to the situation of DCIS patients, where the likelihood of 
progression stands at c. 20–30% and bilateral and unilateral 
mastectomy is performed, respectively, in 10 and 20% of 
cases? For women with atypical hyperplasia, 35% of whom 
will develop breast cancer within the next 30 years [11], 
all we recommend is regular observation! It is difficult to resist 
the impression that we may be guilty of unequal treatment 
and inconsistency in our handling of high-risk patients.
The question of whether we might be treating DCIS 
patients too aggressively is asked with increasing frequency. 
It has been the subject of studies published in top medical 
journals, such as the New England Journal of Medicine [12], 
Lancet Oncology [13], and the Journal of the National Cancer 
Institute [14]. Scholars point out that, paradoxically, the prob-
lem might lie in the efficiency, or rather, the hyper-efficiency 
of our screening systems. Cancer screening relies on several 
premises. The fundamental one is that progression toward 
malignant disease is an ordered and gradual process. The 
second assumes that screening allows identification of can-
cer at an early stage. The last states that early detection 
and effective treatment lead to a significant decrease in 
mortality rates [13]. The three premises have been confirmed 
in clinical practice for cervical and colorectal cancer. Early 
detection of pre-malignant conditions has led to reduc-
tion of the incidence of related cancer cases and resulted 
in decreased mortality rates. In breast cancer, however, the 
impact of screening on mortality is much less significant 
than expected. Importantly, a major increase in the detec-
tion of early-stage (invasive and non-invasive) cases has 
failed to translate into a reduced number of advanced cases 
and generalized cancer incidence [15]. It is very likely that 
our screening tests are too sensitive and detect many early 
conditions that would never pose any threat to patients’ 
lives. Once detected, they are treated with effective but 
aggressive methods that considerably affect patient health.
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This approach to diagnosis and treatment may bring 
a certain sense of satisfaction. We have been very successful 
after all. Breast cancer mortality rates are going down. We 
should be aware, however, that the phenomenon might 
stem not from the lower overall number of deaths, but the 
increased detection of early cases that are not life-threat-
ening to begin with. An old joke tells of a suit vendor who 
decided to increase the discounts on sale items. A suit cost 
100 PLN before and 80 PLN after price reduction. In order 
to further increase the discount, the final price was left 
unchanged (80 PLN), but the original price on the label 
increased to 120 PLN. Isn’t our success in the treatment of 
breast cancer somewhat similar?
It seems that DCIS is a very heterogeneous diagnostic 
category. Some ductal carcinomas in situ with the lowest 
degree of malignancy behave more like atypias and show 
a similar risk of progression, only slightly higher than that 
for an average 65-year-old woman in the general population 
[13]. It has been argued that these DCIS cases are not prop-
erly carcinomas at all; labeling them as “cancer” provokes 
disproportionate fear in patients and compels physicians to 
take unnecessary and excessive treatment measures [12, 13]. 
Instead of aggressive oncological treatment, DCIS patients 
should be recommended to lead an active lifestyle, reduce 
their BMI to max. 25, and take hormonal medication to lower 
the risk of progression to invasive disease [12]. The effective-
ness of tamoxifen in the prevention of breast cancer is the 
same as that of radiation therapy in preventing relapse after 
tumor excision. Surely, there is no need for mastectomy, and 
yet it is still performed in 30% of DCIS patients. 
To recapitulate: efficient imaging techniques have in-
creased the detection of DCIS; in the absence of treatment, 
only ¼ of DCIS cases progress to invasive cancer; current 
treatment is effective, but very aggressive, and, in most 
cases, probably unwarranted.
In order to change that, it is first crucial to modify the 
terminology we use. The “CANCER” label wreaks havoc and 
is not always clinically justified. Changes with a very low risk 
of progression toward invasive carcinoma should be labeled 
as indolent lesions of epithelial origin (IDLE) instead [13]. 
Should the local treatment of DCIS be the same as that 
of early-stage invasive cancer? In most cases, NO. Aggressive 
methods should be avoided unless specifically required. 
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